These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 7683355

  • 1. Pilot study of 5-aza-2'-deoxycytidine (Decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: preliminary results.
    Petti MC, Mandelli F, Zagonel V, De Gregoris C, Merola MC, Latagliata R, Gattei V, Fazi P, Monfardini S, Pinto A.
    Leukemia; 1993 May; 7 Suppl 1():36-41. PubMed ID: 7683355
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Decitabine (5-Aza-2'-deoxycytidine; DAC) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia: preliminary observations.
    Schwartsmann G, Fernandes MS, Schaan MD, Moschen M, Gerhardt LM, Di Leone L, Loitzembauer B, Kalakun L.
    Leukemia; 1997 Mar; 11 Suppl 1():S28-31. PubMed ID: 9130689
    [Abstract] [Full Text] [Related]

  • 4. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia.
    Blum W, Klisovic RB, Hackanson B, Liu Z, Liu S, Devine H, Vukosavljevic T, Huynh L, Lozanski G, Kefauver C, Plass C, Devine SM, Heerema NA, Murgo A, Chan KK, Grever MR, Byrd JC, Marcucci G.
    J Clin Oncol; 2007 Sep 01; 25(25):3884-91. PubMed ID: 17679729
    [Abstract] [Full Text] [Related]

  • 5. Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia.
    Song LX, Xu L, Li X, Chang CK, Zhang Y, Wu LY, He Q, Zhang QX, Li X.
    Ann Hematol; 2012 Dec 01; 91(12):1879-86. PubMed ID: 22895556
    [Abstract] [Full Text] [Related]

  • 6. The role of decitabine for the treatment of acute myeloid leukemia.
    Ganetsky A.
    Ann Pharmacother; 2012 Nov 01; 46(11):1511-7. PubMed ID: 23115225
    [Abstract] [Full Text] [Related]

  • 7. 5-Aza-2'-deoxycytidine (Decitabine) induces trilineage response in unfavourable myelodysplastic syndromes.
    Zagonel V, Lo Re G, Marotta G, Babare R, Sardeo G, Gattei V, De Angelis V, Monfardini S, Pinto A.
    Leukemia; 1993 May 01; 7 Suppl 1():30-5. PubMed ID: 7683354
    [Abstract] [Full Text] [Related]

  • 8. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia.
    Cashen AF, Schiller GJ, O'Donnell MR, DiPersio JF.
    J Clin Oncol; 2010 Feb 01; 28(4):556-61. PubMed ID: 20026803
    [Abstract] [Full Text] [Related]

  • 9. A randomized phase II study on the effects of 5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893).
    Willemze R, Suciu S, Archimbaud E, Muus P, Stryckmans P, Louwagie EA, Berneman Z, Tjean M, Wijermans P, Dohner H, Jehn U, Labar B, Jaksic B, Dardenne M, Zittoun R.
    Leukemia; 1997 Mar 01; 11 Suppl 1():S24-7. PubMed ID: 9130688
    [Abstract] [Full Text] [Related]

  • 10. Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia.
    Kantarjian HM, O'Brien S, Cortes J, Giles FJ, Faderl S, Issa JP, Garcia-Manero G, Rios MB, Shan J, Andreeff M, Keating M, Talpaz M.
    Cancer; 2003 Aug 01; 98(3):522-8. PubMed ID: 12879469
    [Abstract] [Full Text] [Related]

  • 11. Studies of decitabine with allogeneic progenitor cell transplantation.
    Giralt S, Davis M, O'Brien S, van Besien K, Champlin R, de Vos D, Kantarjian H.
    Leukemia; 1997 Mar 01; 11 Suppl 1():S32-4. PubMed ID: 9130690
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
    Cashen AF, Shah AK, Todt L, Fisher N, DiPersio J.
    Cancer Chemother Pharmacol; 2008 Apr 01; 61(5):759-66. PubMed ID: 17564707
    [Abstract] [Full Text] [Related]

  • 13. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG).
    de Witte T, Suciu S, Peetermans M, Fenaux P, Strijckmans P, Hayat M, Jaksic B, Selleslag D, Zittoun R, Dardenne M.
    Leukemia; 1995 Nov 01; 9(11):1805-11. PubMed ID: 7475266
    [Abstract] [Full Text] [Related]

  • 14. DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia.
    Yang AS, Doshi KD, Choi SW, Mason JB, Mannari RK, Gharybian V, Luna R, Rashid A, Shen L, Estecio MR, Kantarjian HM, Garcia-Manero G, Issa JP.
    Cancer Res; 2006 May 15; 66(10):5495-503. PubMed ID: 16707479
    [Abstract] [Full Text] [Related]

  • 15. 5-Aza-2'-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation.
    Scott SA, Dong WF, Ichinohasama R, Hirsch C, Sheridan D, Sanche SE, Geyer CR, Decoteau JF.
    Leuk Res; 2006 Jan 15; 30(1):69-76. PubMed ID: 16043219
    [Abstract] [Full Text] [Related]

  • 16. Preliminary results with 5-aza-2'-deoxycytidine (DAC)-containing chemotherapy in patients with relapsed or refractory acute leukemia. The EORTC Leukemia Cooperative Group.
    Willemze R, Archimbaud E, Muus P.
    Leukemia; 1993 May 15; 7 Suppl 1():49-50. PubMed ID: 7683357
    [Abstract] [Full Text] [Related]

  • 17. Decitabine for acute myeloid leukemia.
    Marks PW.
    Expert Rev Anticancer Ther; 2012 Mar 15; 12(3):299-305. PubMed ID: 22369322
    [Abstract] [Full Text] [Related]

  • 18. Decitabine.
    Hackanson B, Daskalakis M.
    Recent Results Cancer Res; 2014 Mar 15; 201():269-97. PubMed ID: 24756800
    [Abstract] [Full Text] [Related]

  • 19. Second complete remission in an elderly patient with acute myeloid leukemia retreated with decitabine.
    Cashen AF, Devine H, DiPersio J.
    Am J Hematol; 2006 Jul 15; 81(7):543-5. PubMed ID: 16755561
    [Abstract] [Full Text] [Related]

  • 20. Clinical development of decitabine as a prototype for an epigenetic drug program.
    Rosenfeld CS.
    Semin Oncol; 2005 Oct 15; 32(5):465-72. PubMed ID: 16210087
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.